190 related articles for article (PubMed ID: 20222991)
1. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
[TBL] [Abstract][Full Text] [Related]
2. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
Enjoji M; Nakamuta M
World J Gastroenterol; 2010 Feb; 16(7):800-3. PubMed ID: 20143458
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
4. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
6. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
8. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol.
Yasutake K; Nakamuta M; Shima Y; Ohyama A; Masuda K; Haruta N; Fujino T; Aoyagi Y; Fukuizumi K; Yoshimoto T; Takemoto R; Miyahara T; Harada N; Hayata F; Nakashima M; Enjoji M
Scand J Gastroenterol; 2009; 44(4):471-7. PubMed ID: 19058085
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Fukuda M; Nakamura T; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yasuda O; Ogawa H; Kim-Mitsuyama S
J Pharmacol Exp Ther; 2010 Oct; 335(1):70-5. PubMed ID: 20651026
[TBL] [Abstract][Full Text] [Related]
13. The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1.
Ge L; Wang J; Qi W; Miao HH; Cao J; Qu YX; Li BL; Song BL
Cell Metab; 2008 Jun; 7(6):508-19. PubMed ID: 18522832
[TBL] [Abstract][Full Text] [Related]
14. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Ahmed MH; Byrne CD
Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
Nomura M; Ishii H; Kawakami A; Yoshida M
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver.
Tang W; Jia L; Ma Y; Xie P; Haywood J; Dawson PA; Li J; Yu L
Biochim Biophys Acta; 2011 Sep; 1811(9):549-55. PubMed ID: 21683156
[TBL] [Abstract][Full Text] [Related]
18. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.
Temel RE; Tang W; Ma Y; Rudel LL; Willingham MC; Ioannou YA; Davies JP; Nilsson LM; Yu L
J Clin Invest; 2007 Jul; 117(7):1968-78. PubMed ID: 17571164
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease.
Park H; Shima T; Yamaguchi K; Mitsuyoshi H; Minami M; Yasui K; Itoh Y; Yoshikawa T; Fukui M; Hasegawa G; Nakamura N; Ohta M; Obayashi H; Okanoue T
J Gastroenterol; 2011 Jan; 46(1):101-7. PubMed ID: 20658156
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy of ezetimibe on nonalcoholic fatty liver disease (NAFLD)].
Shiwa T; Kawanami Y; Yokoyama T; Moritani A; Hashimoto M; Gotoh T
Nihon Shokakibyo Gakkai Zasshi; 2011 Aug; 108(8):1383-92. PubMed ID: 21817841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]